全文获取类型
收费全文 | 4062篇 |
免费 | 490篇 |
国内免费 | 11篇 |
专业分类
耳鼻咽喉 | 15篇 |
儿科学 | 155篇 |
妇产科学 | 451篇 |
基础医学 | 377篇 |
口腔科学 | 98篇 |
临床医学 | 1031篇 |
内科学 | 647篇 |
皮肤病学 | 113篇 |
神经病学 | 332篇 |
特种医学 | 294篇 |
外科学 | 238篇 |
综合类 | 96篇 |
一般理论 | 2篇 |
预防医学 | 288篇 |
眼科学 | 30篇 |
药学 | 129篇 |
中国医学 | 4篇 |
肿瘤学 | 263篇 |
出版年
2023年 | 50篇 |
2021年 | 32篇 |
2020年 | 49篇 |
2019年 | 59篇 |
2018年 | 103篇 |
2017年 | 124篇 |
2016年 | 119篇 |
2015年 | 126篇 |
2014年 | 149篇 |
2013年 | 156篇 |
2012年 | 145篇 |
2011年 | 171篇 |
2010年 | 147篇 |
2009年 | 145篇 |
2008年 | 147篇 |
2007年 | 145篇 |
2006年 | 133篇 |
2005年 | 124篇 |
2004年 | 96篇 |
2003年 | 130篇 |
2002年 | 90篇 |
2001年 | 110篇 |
2000年 | 103篇 |
1999年 | 108篇 |
1998年 | 128篇 |
1997年 | 130篇 |
1996年 | 127篇 |
1995年 | 113篇 |
1994年 | 85篇 |
1993年 | 60篇 |
1992年 | 61篇 |
1991年 | 75篇 |
1990年 | 61篇 |
1989年 | 89篇 |
1988年 | 92篇 |
1987年 | 61篇 |
1986年 | 69篇 |
1985年 | 72篇 |
1984年 | 46篇 |
1983年 | 38篇 |
1982年 | 40篇 |
1981年 | 30篇 |
1980年 | 32篇 |
1979年 | 28篇 |
1978年 | 34篇 |
1977年 | 30篇 |
1976年 | 38篇 |
1975年 | 37篇 |
1974年 | 26篇 |
1973年 | 25篇 |
排序方式: 共有4563条查询结果,搜索用时 15 毫秒
71.
Understanding the experience of women admitted to a psychiatric hospital in Sydney with psychosis or mania following childbirth after World War II (1945–1955) 下载免费PDF全文
72.
73.
74.
Systematic review with meta‐analysis: magnetic resonance enterography signs for the detection of inflammation and intestinal damage in Crohn's disease 下载免费PDF全文
75.
Greer Lamaro Haintz Melissa Graham Hayley McKenzie 《Health promotion journal of Australia》2015,26(3):235-240
Health promotion researchers must consider the ethics of their research, and are usually required to abide by a set of ethical requirements stipulated by governing bodies (such as the Australian National Health and Medical Research Council) and human research ethics committees (HRECs). These requirements address both deontological (rule‐based) and consequence‐based issues. However, at times there can be a disconnect between the requirements of deontological issues and the cultural sensitivity required when research is set in cultural contexts and settings etic to the HREC. This poses a challenge for health promotion researchers who must negotiate between meeting both the requirements of the HREC and the needs of the community with whom the research is being conducted. Drawing on two case studies, this paper discusses examples from cross‐cultural health promotion research in Australian and international settings where disconnect arose and negotiation was required to appropriately meet the needs of all parties. The examples relate to issues of participant recruitment and informed consent, participants under the Australian legal age of consent, participant withdrawal when this seemingly occurs in an ad hoc rather than a formal manner and reciprocity. Although these approaches are context specific, they highlight issues for consideration to advance more culturally appropriate practice in research ethics and suggest ways a stronger anthropological lens can be applied to research ethics to overcome these challenges. 相似文献
76.
Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia 总被引:4,自引:0,他引:4
Pavletic ZS Arrowsmith ER Bierman PJ Goodman SA Vose JM Tarantolo SR Stein RS Bociek G Greer JP Wu CD Kollath JP Weisenburger DD Kessinger A Wolff SN Armitage JO Bishop MR 《Bone marrow transplantation》2000,25(7):717-722
The objective of this study was to describe the outcome of allogeneic stem cell transplantation (alloSCT) in a series of patients with B cell chronic lymphocytic leukemia (B-CLL). Twenty-three B-CLL patients were transplanted between 1988 and 1997 using stem cells from a related (n = 20) or an unrelated donor (n = 3). The median age of the patients was 46 years, and the median number of prior chemotherapy regimens received was two. At transplantation, 14 patients had chemorefractory disease and 12 of these were refractory to fludarabine. The preparative regimens included total body irradiation (TBI) in 22 of the 23 cases. All patients received graft-versus-host disease (GVHD) prophylaxis with cyclosporine and methotrexate. Twenty patients (87%) achieved a complete remission (CR). The incidence of grade II-IV acute GVHD was 54%. Fourteen (61%) patients are alive and disease-free, including two with unrelated donors, at a median of 26 months (range, 9-115 months). Nine patients (39%) have died, one of whom had progressive B-CLL. The only favorable prognostic factor for failure-free survival (FFS) and overall survival (OS) after alloSCT was the use of a cyclophosphamide/TBI rather than an etoposide/cyclophosphamide/TBI regimen (P = 0.03). The projected 5-year FFS, OS, and relapse rates after alloSCT were 65% (95% CI, 48-88%), 62% (95% CI, 43-88%), and 5% (95%, CI 0-13%), respectively. These findings demonstrate the potential of high-dose therapy and alloSCT for inducing and maintaining a remission in patients with advanced or chemorefractory B-CLL. The low relapse rate may be due to an allogeneic graft-versus-leukemia effect. 相似文献
77.
Recombinant human thrombopoietin (rhTPO) after autologous bone marrow transplantation: a phase I pharmacokinetic and pharmacodynamic study 总被引:2,自引:0,他引:2
Wolff SN Herzig R Lynch J Ericson SG Greer JP Stein R Goodman S Benyunes MC Ashby M Jones DV Fay J 《Bone marrow transplantation》2001,27(3):261-268
Thrombocytopenia following myelotoxic therapy is a common problem and when severe (<20,000/microl) can lead to severe morbidity and mortality. Thrombopoietin (TPO) is a naturally occurring glycosylated peptide which stimulates the differentiation of bone marrow stem cells into megakaryocyte progenitor cells, induces the expression of megakaryocyte differentiation markers, promotes megakaryocyte proliferation, polyploidization and, ultimately, the formation of increased numbers of platelets in the circulation. TPO has now been produced by recombinant technology and has entered clinical trials. This open label phase I study was designed to determine the safety, tolerance and pharmacokinetics of recombinant thrombopoietin (rhTPO) when administered to patients after undergoing high-dose chemotherapy followed by autologous bone marrow transplantation. rhTPO was administered intravenously by bolus injection at doses ranging from 0.3 to 4.8 microg/kg/day every 3 days to 30 patients and 0.6 microg/kg daily to three patients. rhTPO was begun the day after marrow infusion and continued until platelet recovery to >20,000/microl. G-CSF was concomitantly administered to promote myeloid recovery. Serious adverse events or neutralizing antibodies to rhTPO were not observed during the study. Median platelet recovery after ABMT was 19 days (range, 11-41). Neither the dose nor the schedule of rhTPO appeared to have any impact upon the time course of platelet recovery. In this phase I study, rhTPO was found to be well tolerated without the development of neutralizing antibodies and without compromising neutrophil recovery. Platelet recovery was similar for all doses studied warranting further evaluation in phase II and III trials designed to test for platelet recovery efficacy. 相似文献
78.
Steinberg JS Beckman K Greene HL Marinchak R Klein RC Greer SG Ehlert F Foster P Menchavez E Raitt M Wathen MS Morris M Hallstrom A 《Journal of cardiovascular electrophysiology》2001,12(9):996-1001
INTRODUCTION: A prospective registry and substudy were conducted in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Study to clarify the prognosis and recurrent event rate, risk factors, and impact of implantable cardioverter defibrillator (ICD) therapy in patients with unexplained syncope, structural heart disease, and inducible ventricular tachyarrhythmias. METHODS AND RESULTS: Included in the AVID registry were patients from all participating sites who had "out of hospital syncope with structural heart disease and EP-inducible VT/VF with symptoms." In addition, 13 collaborating sites provided more in-depth clinical and electrophysiologic data as part of a formal prospective substudy. Patients in the substudy were followed by local investigators for recurrent arrhythmic events and mortality. Registry patients were tracked for fatal outcomes by the National Death Index. A total of 429 patients with syncope were entered in the AVID registry, of whom 80 participated in the substudy. Of the substudy patients, 21 patients (26%) had inducible polymorphic ventricular tachycardia/ventricular fibrillation (VT/VF), 11 patients (14%) had sustained monomorphic VT <200 beats/min, and 48 patients (60%) had sustained monomorphic VT > or = 200 beats/min. The ICD was used as sole therapy in 75% of the syncope substudy patients (and with antiarrhythmic drug in an additional 9%) and in 59% of the syncope registry patients. Survival rates at 1 and 3 years were 93% and 74% for the substudy patients and 90% and 74% for the registry patients, respectively. Survival of the syncope substudy patients (predominantly treated by ICD) was similar to the VT patients treated by ICD and superior to the VT patients treated by an antiarrhythmic drug (P = 0.05) in the randomized main trial. Mortality events in the substudy were marginally predicted by ejection fraction (P = 0.06) but not by electrophysiologic study-induced arrhythmia. The significant predictor of increased mortality in the registry was age (P = 0.003) and of reduced mortality was treatment with ICD (P = 0.006). CONCLUSION: The results of these analyses support the role of the ICD as primary antiarrhythmic therapy in patients with unexplained syncope, structural heart disease, and inducible VT/VF at electrophysiologic study. 相似文献
79.
JD Roberts JC Herkert J Rutberg SM Nikkel ACP Wiesfeld D Dooijes RM Gow JP van Tintelen MH Gollob 《Clinical genetics》2013,83(5):452-456
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited myocardial disease that predominantly affects the right ventricle and is associated with ventricular arrhythmias that may lead to sudden cardiac death. Mutations within at least seven separate genes have been identified to cause ARVC, however a genetic culprit remains elusive in approximately 50% of cases. Although negative genetic testing may be secondary to pathogenic mutations within undiscovered genes, an alternative explanation may be the presence of large deletions or duplications involving known genes. These large copy number variants may not be detected with standard clinical genetic testing which is presently limited to direct DNA sequencing. We describe two cases of ARVC possessing large deletions involving plakophilin‐2 (PKP2) identified with microarray analysis and/or multiplex ligation‐dependent probe amplification (MLPA) that would have been classified as genotype negative with standard clinical genetic testing. A deletion of the entire coding region of PKP2 excluding exon 1 was identified in patient 1 and his son. In patient 2, MLPA analysis of PKP2 revealed deletion of the entire gene with subsequent microarray analysis demonstrating a de novo 7.9 Mb deletion of chromosome 12p12.1p11.1. These findings support screening for large copy number variants in clinically suspected ARVC cases without clear disease causing mutations following initial sequencing analysis. 相似文献